Does transcatheter aortic valve implantation with the Evolut platform provide favorable valve performance and clinical outcomes in patients with bicuspid aortic stenosis?
TAVI with the Evolut platform appears to offer favorable valve performance and clinical outcomes for treating bicuspid aortic stenosis, independent of the sizing methodology used.
BIVOLUTX demonstrated a favourable bioprosthetic valve performance and good clinical outcomes after TAVI with the Evolut platform in patients with bicuspid aortic stenosis. No impact from the sizing methodology could be identified.
Tchétché et al. (Tue,) studied this question.